GLP Agonists — News & Regulatory Updates https://glpagonists.com/news.html FDA news, regulatory updates, and clinical evidence on GLP-1 telehealth and peptide therapy. Updated weekly. en-us © 2026 GLP Agonists glpagonists@gmail.com (Adam Kennah, MD) glpagonists@gmail.com Mon, 05 May 2026 00:00:00 GMT FDA Approves Foundayo (Orforglipron) — First Oral GLP-1 Small Molecule https://glpagonists.com/news.html#foundayo-approval glpagonists-foundayo-approval-20260401 Wed, 01 Apr 2026 00:00:00 GMT GLP Agonists Editorial Foundayo (orforglipron) received FDA approval April 1, 2026 under the Commissioner's National Priority Voucher pilot — the first oral GLP-1 small molecule approved for weight management. Approved on a 50-day review timeline, it represents the first non-injectable GLP-1 receptor agonist option for patients. FDA Resolution of GLP-1 Shortages: Compounded Enforcement Timeline https://glpagonists.com/news.html#compounded-enforcement glpagonists-compounded-enforcement-2025 Thu, 22 May 2025 00:00:00 GMT GLP Agonists Editorial Following the FDA's declaration that the GLP-1 shortage was resolved, enforcement discretion for compounded preparations ended on a phased schedule: compounded tirzepatide at 503A pharmacies (Feb 18, 2025); compounded tirzepatide at 503B (March 19, 2025); compounded semaglutide at 503A (April 22, 2025); compounded semaglutide at 503B (May 22, 2025). Compounded versions may now only be prescribed where a licensed provider documents medical necessity. NexLife Named Editor's Top Pick for 2026 GLP-1 Telehealth https://glpagonists.com/nexlife.html https://glpagonists.com/nexlife.html Mon, 05 May 2026 00:00:00 GMT GLP Agonists Editorial NexLife earns our 2026 Editor's Top Pick on the strength of bundled flat-rate pricing ($165/mo compounded semaglutide, $215/mo compounded tirzepatide), free expedited shipping, no subscription lock-in, 503A pharmacy sourcing with USP <85> testing, and LegitScript certification.